Search PubMed⌕ Search

Biomedical subjects

C Lister

Publications and source records attributed to C Lister.

49 records · Page 3Linked to original sources
PubMed1980

The effects of homologous cross-circulation and in situ liver perfusion on fulminant hepatic failure rats.

A galactosamine-induced fulminant hepatic failure (FHF) rat model was used to study the effects of homologous cross-circulation and in situ liver perfusion. Cross-circulation with homologous donors did not significantly improve the survival time or recovery rate of grade II hepatic coma rats. Homologous in situ liver perfusion significantly improved the survival time and recovery in FHF only when started in grade II coma; it has no effect in the later stage of coma.

Animals↗
PubMed1979

Long-term clinical assessment of combined ACAC hemoperfusion-ultrafiltration in uremia.

ACAC hemoperfusion was used in series with a small fluid removal system for a clinical trial in the treatment of uremia. A 22-month trial included a pretest control period, test period and a post-test control period. The most significant observations from this trial are: 1) the predialysis body weight of the patient could be maintained closer to the patient's dry weight; 2) there was a significant increase in hematocrit; and 3) there was insufficient removal of urea. With the development of an effective urea removal system, a more compact artificial kidney than any presently available will become feasible.

Blood Chemical Analysis↗
PubMed1979

Biochemical, hematological and histological changes in a fulminant hepatic failure rat model for artificial liver assessment.

Galactosamine-induced fulminant hepatic failure rats have been used as a model for statistical assessment of liver support systems. The present study reports in detail the biochemical, hematological and histological changes in these animals. They have been used to study statistically the effects of ACAC charcoal hemoperfusion, cross-circulation and liver perfusion on long-term survival in fulminant hepatic failure.

Animals↗
PubMed1977

Artificial liver: the effect of ACAC microencapsulated charcoal hemoperfusion on fulminant hepatic failure.

Control trials and statistical analysis were carried out to assess the effects of albumin-collodion microencapsulated activated charcoal (ACAC) hemoperfusion on fulminant hepatic coma. A rat model of galactosamine induced fulminant hepatic coma was used. Rats which did not recover died at 3.0+/-0.6 days after galactosamine injection. Those which survived this period recovered. Forty-eight hours after galactosamine injection, a test group of 21 rats were treated with 1 hour hemoperfusion and compared with an untreated group of 23 rats. 71.4% of the treated group survived as compared to 30.4% of the untreated rats. Statistical analysis (t test) shows a significant increase in recovery for the treated group (less than 0.01). Biochemical and histological results will be discussed.

Albumins↗
PubMed1977

Clinical evaluation of the clearance profiles of a portable, compact, dialysate-free system incorporating microencapsulated charcoal hemoperfusion for blood purification with ultrafiltration for fluid removal.

A total of 30 procedures have been carried out in two patients using a new portable, compact, dialysate-free system formed by combining 300 gms of albumin--cellulose nitrate microencapsulated activated charcoal (ACAC) in series with a small Amicon ultrafiltrator. Blood passing through the ACAC hemoperfusion system is purified of waste metabolites and toxins. Fluid removal is carried out with the hydrostatic pressure of the blood passing through the dialysate-free ultrafiltrator. Since ACAC hemoperfusion is much more efficient than hemodialysers for blood purification, the combined system with the ultrafiltrator results in a very efficient system for blood purification and fluid removal. Typical clearance data for the combined systems include: 75 ml/min for 2000--5000 MW; 112.7 ml/min for 300--1500 MW; 235 ml/min for creatinine; 240 ml/min for uric acid; 2500--2700 ml/2 hours for water removal; and 17--18 gm/2 hours for NaCl removal. Guanidines, mercaptans, and PTH are also cleared very efficiently.

Charcoal↗
PubMed1973

Microcapsule artificial kidney: treatment of patients with acute drug intoxication.

The microcapsule artificial kidney was used in the treatment of three patients with acute drug intoxication. The apparatus contains 300 g. of microencapsulated activated charcoal with a total membrane area available for diffusion of more than 2m.(2) The membrane thickness is only 500 A. These properties make possible a compact artificial kidney whose efficiency for the removal of uremic metabolites and drugs is much higher than standard hemodialysis apparatus. The microcapsules are made blood-compatible by coating with human albumin. A roller pump was used to propel the blood through the microcapsule artificial kidney at a flow rate of 300 ml./min. for two to three hours. The clearance values for glutethimide, methyprylon and methaqualone were much higher than those achieved by standard hemodialysis. Hemoperfusion quickly lowered the drug level in the blood with resulting clinical improvement.

Adult↗
PubMedDate not supplied

Plasma/intestinal concentration patterns suggestive of entero-portal recirculation of amino acids: effects of oral administration of asparaginase, glutaminase and tyrosinase immobilized by microencapsulation in artificial cells.

This study suggests the presence of an entero-portal recirculation of amino acids. Endogenous sources of amino acids are secreted at high concentration into the small intestine. Most of the amino acids are absorbed as the content passes down the small intestine. Plasma amino acid concentrations are on the average only 1-5% of the concentrations in the duodunum. This is true even in rats on 24 hours of water and sugar with no exogenous sources of amino acids. For example, the PLASMA:DUODENUM concentrations (mumole/litre) are: Asparagine 37:7164, Tyrosine 94:9579, and glutamine/histidine 409:9708. This entero-portal recirculation of amino acids means the potential of a method for specific depletion of body amino acids by oral ingestion of bioreactants like immobilized enzymes. Preliminary studies used artificial cells to immobilize asparaginase,glutaminase and tyrosinase by microencapsulation. Six hours after 1 oral administration, asparagine, glutamine and tyrosine in the ileum were lowered to 10% of the level of the control. Artificial cells containing no enzymes were used as the control.

Administration, Oral↗